Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

1. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19

in the diagram:: Angiotensinogen is converted to angiotensin I by renin. Angiotensin I (a decapeptide) is converted by ACE-1 to angiotensin II (an octapeptide). Angiotensin II is an agonist at both angiotensin AT 1 and angiotensin AT 2 receptors. Angiotensin I is also converted, by ACE-2, to the nonapeptide angiotensin(1-9). Angiotensin II is also converted, by ACE-2, to the heptapeptide angiotensin(1-7). Angiotensin (1-9) is converted, by ACE-1, to angiotensin(1-7). ACE-1 inhibitors inhibit the conversion (...) or the action of another protease, cathepsin (b) The same serine protease, TMPRSS2, causes irreversible conformational changes in the virus’s S2 subunits, activating them, after which the virus fuses to the cell membrane and can be internalized by the cell A serine protease inhibitor, camostat mesylate, used in Japan to treat , inhibits the TMPRSS2 and partially into bronchial epithelial cells in vitro. Analysis Reducing the activity of ACE-2 in cell membranes could theoretically reduce the ability of SARS

2020 Oxford COVID-19 Evidence Service

2. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser. Did you (...) know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. . ESC sub specialties communities Search Read your latest personalised notifications No account yet? Don't miss out Read your latest personalised notifications Loading quicklinks... Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers 13 Mar 2020 Based on initial reports from China, and subsequent evidence

2020 European Society of Cardiology

3. Should ACE Inhibitors and Angiotensin II Receptor Blockers be Stopped for COVID-19

Should ACE Inhibitors and Angiotensin II Receptor Blockers be Stopped for COVID-19 MOH-ACE COVID-19 RAPID REVIEW 21 March 2020 Page 1 of 2 Clinical evidence Background Should ACE inhibitors and angiotensin II receptor blockers be stopped for COVID-19? This write-up summarises a rapid evidence review related to COVID-19. The information may be revised as new evidence emerges. Two recent articles by Madeddu in the British Medical Journal (BMJ) and Fang et al. in the Lancet Respiratory Medicine (...) have raised concerns about angiotensin-converting enzyme inhibitors (ACE-i) and angiotensin II receptor blockers (ARB) potentially increasing the risk of COVID-19 and related respiratory distress syndrome. 1,2 The authors hypothesise that angiotensin-converting enzyme 2 (ACE2) is upregulated in patients treated with ACE-i or ARB, which would facilitate COVID-19 infection as ACE2 is a functional receptor of the virus. 3 Madeddu maintains that ACE-i and ARB should not be suspended due to the lack

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

4. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Rights OpenAccess. This work

2019 PURLS

5. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Rights OpenAccess. This work

2019 PURLS

6. ACE inhibitors

ACE inhibitors Top results for ace inhibitors - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 (...) or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ace inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other

2018 Trip Latest and Greatest

7. Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?

Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes (...) and normal BP? View/ Open Date 2017-04 Format Metadata Abstract Q: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Evidence-based answer: Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). In normotensive patients with type 1 and type 2 diabetes, ACE inhibitor therapy reduces the risk of developing diabetic kidney disease, defined as new-onset microalbuminuria or macroalbuminuria, by 18% (strength

2018 Clinical Inquiries

8. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. Full Text available with Trip Pro

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated in adolescents.We (...) screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion, assessed according

2017 NEJM Controlled trial quality: predicted high

9. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease Full Text available with Trip Pro

Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease Cognitive improvement has been reported in patients receiving centrally acting angiotensin-converting enzyme inhibitors (C-ACEIs).To compare cognitive decline and survival after diagnosis of Alzheimer's disease between people receiving C-ACEIs, non-centrally acting angiotensin-converting enzyme inhibitors (NC-ACEIs), and neither.Routine Mini-Mental State Examination (MMSE) scores were (...) extracted in 5260 patients receiving acetylcholinesterase inhibitors and analysed against C-/NC-ACEI exposure at the time of Alzheimer's disease diagnosis.In the 9 months after Alzheimer's disease diagnosis, MMSE scores significantly increased by 0.72 and 0.19 points per year in patients on C-ACEIs and neither respectively, but deteriorated by 0.61 points per year in those on NC-ACEIs. There were no significant group differences in score trajectories from 9 to 36 months and no differences in survival.In

2017 BJPsych open

10. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

2017 Prescrire

11. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Full Text available with Trip Pro

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual pathway (...) antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed in acute coronary syndromes. We aimed to assess rivaroxaban 2·5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or ticagrelor (chosen at investigator discretion before randomisation), for patients with acute coronary syndromes started within 10 days after presentation and continued for 6-12 months.In this double-blind, multicentre, randomised trial (GEMINI

2017 Lancet Controlled trial quality: predicted high

12. ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

14. EXAMINING EXAMINE FOR AN INTERACTION WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITION Full Text available with Trip Pro

EXAMINING EXAMINE FOR AN INTERACTION WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITION 27480841 2018 01 16 2018 12 02 1524-4563 68 3 2016 09 Hypertension (Dallas, Tex. : 1979) Hypertension Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. 549-51 10.1161/HYPERTENSIONAHA.116.07884 Wilson Jessica R JR From the Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. Brown Nancy J NJ From the Department of Medicine, Vanderbilt University (...) Medical Center, Nashville, TN. Nancy.j.brown@vanderbilt.edu. eng R01 HL125426 HL NHLBI NIH HHS United States T32 DK007061 DK NIDDK NIH HHS United States T32 GM007569 GM NIGMS NIH HHS United States Editorial Research Support, N.I.H., Extramural Comment 2016 08 01 United States Hypertension 7906255 0194-911X 0 Angiotensin-Converting Enzyme Inhibitors EC 3.4.15.1 Peptidyl-Dipeptidase A IM Hypertension. 2016 Sep;68(3):606-13 27480840 Angiotensin-Converting Enzyme Inhibitors Humans Peptidyl-Dipeptidase

2016 Hypertension (Dallas, Tex. : 1979)

15. Cohort study: ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives

Cohort study: ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives

2016 Evidence-Based Medicine

16. Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines

Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines | CADTH.ca Find the information you need Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Published on: November 26, 2015 Project Number: RB0938-000 Product Line: Research Type: Drug (...) Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the treatment of patients with angiotensin-converting enzyme inhibitor-induced angioedema? Key Message Four evidence-based guidelines were identified regarding the treatment of patients with angiotensin-converting enzyme inhibitor-induced angioedema. Tags angioedema, angioneurotic edema, quincke's edema, angio-oedema, angiooedema Files Rapid Response Summary of Abstracts Published

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Angiotensin-Converting Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness

. Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis. Ochsner J [Internet]. 2014 [cited 2015 May 20];14(3):350-8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171793 14. Huang SS, Wu TC, Lin SJ, Chen JW. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J [Internet]. 2009 Dec [cited 2015 May (...) = 0.041). Preterax significantly increased the plasma insulin concentration (P ? The combination of an ACEI and indapamide improved BP control, but attenuated the beneficial effects of ACE inhibition on plasma adiponectin. ? This combination would be best suited for improving BP control rather than for metabolic protection. ACE Inhibitors 21 Table A1: Summary of Findings of Included Studies Main Study Findings Author’s Conclusions = 0.041). McLaughlin, 2008 12 Combination of captopril

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Full Text available with Trip Pro

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long-standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding significant (...) increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a strong predictor of subsequent renal failure. There is extensive experience and evidence with angiotensin-converting enzyme (ACE) inhibitors over many years in a variety of clinical situations for patients who do not have sickle cell disease, but their effect in people with this disease is unknown. It is common practice to administer ACE inhibitors for sickle nephropathy due to their renoprotective

2015 Cochrane

19. Icatibant in ACE-Inhibitor-Induced Angioedema. Full Text available with Trip Pro

Icatibant in ACE-Inhibitor-Induced Angioedema. 25946292 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Icatibant in ACE-inhibitor-induced angioedema. 1866 10.1056/NEJMc1503671 Tomkiewicz William W eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Angiotensin-Converting Enzyme Inhibitors 0 Bradykinin B2 Receptor Antagonists S8TIM42R2W Bradykinin AIM IM N Engl J Med. 2015 Jan 29;372(5):418-25 25629740 N Engl J Med. 2015 May (...) 7;372(19):1867-8 25946291 Angioedema drug therapy Angiotensin-Converting Enzyme Inhibitors adverse effects Bradykinin analogs & derivatives Bradykinin B2 Receptor Antagonists therapeutic use Female Humans Male 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946292 10.1056/NEJMc1503671 10.1056/NEJMc1503671#SA1

2015 NEJM

20. Icatibant in ACE-Inhibitor-Induced Angioedema. Full Text available with Trip Pro

Icatibant in ACE-Inhibitor-Induced Angioedema. 25946293 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Icatibant in ACE-inhibitor-induced angioedema. 1866 10.1056/NEJMc1503671 Soo Hoo Guy W GW Klaustermeyer William B WB eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Angiotensin-Converting Enzyme Inhibitors 0 Bradykinin B2 Receptor Antagonists S8TIM42R2W Bradykinin AIM IM N Engl J Med. 2015 Jan 29;372(5):418-25 25629740 N (...) Engl J Med. 2015 May 7;372(19):1867-8 25946291 Angioedema drug therapy Angiotensin-Converting Enzyme Inhibitors adverse effects Bradykinin analogs & derivatives Bradykinin B2 Receptor Antagonists therapeutic use Female Humans Male 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946293 10.1056/NEJMc1503671 10.1056/NEJMc1503671#SA2

2015 NEJM